Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

This often causes symptoms of diarrhea, bloody diarrhea, crampy abdominal pain, urgency, and pain on the left side of the abdomen. This form of ulcerative colitis may also be called limited or ...

Oral colon-release parnaparin sodium tablets are safe and effective as an adjunctive therapy to aminosalicylates in patients with ulcerative colitis ... with active left-sided ulcerative colitis.

distal ulcerative colitis who had received corticosteroids for >2 weeks without improvement (16 with left-sided colitis, 4 with pancolitis) were treated with rebamipide enemas twice a day for 3 ...

The lesion extent of the disease can be classified as proctitis, proctosigmoiditis, left-sided colitis, extensive colitis, pancolitis, and regional colitis. Left-sided colitis refers to ...

Background and Aims: Both clinical outcomes and factors predictive for poor response after an initial course of corticosteroids have not yet been well established in the treatment of moderate to ...